8:00 am Chair’s Opening Remarks

Preclinical Models: Recapitulating the Human Neuroimmune System

8:15 am Using iPS-Microglia & Chimeric Models to Examine the Neuroimmunology of Alzheimer’s Disease

  • Matt Blurton-Jones Associate Professor, Department of Neurobiology & Behavior, University of California, Irvine

8:45 am Development of Targets Identified from Patients & Validated With Ex Vivo & In Vivo Models of Neuroinflammation

  • Sue Bruhn Chief Executive Officer & President, Tiaki Therapeutics

9:15 am Audience Discussion: Working with the Right Cells In Vitro

9:45 am Morning Refreshments & Networking

Improving Biological Understanding of Innate Immunity in the CNS

10:45 am TREM2, from Basic Functions to a Therapeutic Target

  • Christian Haass Professor, Laboratory of Neurodegenerative Disease, University of Munich

11:15 am The Role of Innate Immune Dysfunction & Chronic Inflammatory Disease in Neurodegeneration

  • Malu Tansey Director, Center for Translational Research in Neurodegenerative Disease & the Parkinson’s Foundation Research Center, The University of Florida College of Medicine

11:45 am SAM Microglia, a Novel Storage-Body Accumulating Subset in Steady- State & Aging

12:15 pm Lunch & Networking

1:15 pm Beyond the Usual Suspects: Promoting Novel Thinking

1:45 pm The Michael J. Fox Foundation’s Efforts to Improve Understanding of Inflammation in Parkinson’s Disease

  • Nicole Polinsky Senior Associate Director, Research Programs, The Michael J Fox Foundation


• Discussing MJFF’s investment in uncovering and improving inflammation-related
biomarkers for Parkinson’s disease
• Highlighting our inflammation-related strategy to date and the strategy we seek
to employ for the coming years
• Providing an overview of the MJFF funding programs and additional resources
MJFF provides to support Parkinson’s disease research

2:15 pm Panel Discussion: Investing in Neuroinflammatory Targets & Backing Smaller Companies Research

Reviewing Clinical Data to Inform Future Drug Development

2:45 pm Recipe for Success: Design Neuro Trials to Look Like Oncology Trials!

  • RJ Tesi Chief Executive Officer & Chief Medical Officer, INmune Bio

2:45 pm Afternoon Networking & Refreshments

3:45 pm Discovery to Clinical Evaluation of Neuroinflammation: The Microglial P2X7-NLRP3 Axis

4:15 pm Reviewing Early Biomarker Read Outs to Improve Drug Development

4:45 pm Panel Discussion: Optimizing Clinical Trial Study Design & Finding the Appropriate Controls for Patients

  • Robert Paul Chief Medical Officer, Alector
  • RJ Tesi Chief Executive Officer & Chief Medical Officer, INmune Bio

5:15 pm Chair’s Closing Remarks